Filing Flows › Lenz Therapeutics (LENZ) › Guidance & outlook
Lenz Therapeutics (LENZ) guidance and outlook
Lenz Therapeutics (LENZ) gave its guidance on Oct 28, 2026: Operating expenses +50% for FY2027; Operating expenses $70.0M–$75.0M for FY2027. Lenz Therapeutics' 10-Q filed Nov 3, 2026 makes 17 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Operating expenses | FY2027 | +50% | new |
| Operating expenses | FY2027 | $70.0M–$75.0M | new |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- We expect to continue to incur significant expenses related to product sales, marketing, manufacturing, and distribution of VIZZ as we are in the early stages of commercialization, and additional costs associated with being a public company, including audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements.
- We expect to continue to incur expenses necessary to support our commercial strategy, including our direct-to-consumer (“DTC”) marketing campaign.
- We expect our selling, general and administrative expenses to decrease following the strategic reorganization announced in October 2026, which is expected to be substantially completed during the fourth quarter of 2026.
- We expect our research and development costs will be de minimis over the remainder of 2026.
- Prescriptions will be automatically routed and fulfilled by our ePharmacy partner providing a seamless and convenient consumer journey from product interest to home delivery.
- Launch of the telehealth channel will be promoted alongside our
- The charges we expect to incur in connection with this strategic reorganization are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ.
- Chevallard will continue to serve in his role as our Chief Financial Officer in addition to his role as interim President and Chief Executive Officer.
- We expect to continue to incur significant expenses and operating losses as we continue commercialization of VIZZ, including costs related to product sales, marketing, manufacturing, and distribution.
- This belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than expected.
- Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than currently anticipated, and we may need to seek additional funds sooner than planned.
- We believe that our existing cash, cash equivalents, and marketable securities through the date of filing of this report will be sufficient to support our operations for at least the next 12 months.
Lenz Therapeutics' latest quarter
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did Lenz Therapeutics raise or lower its guidance?
Lenz Therapeutics (LENZ) gave its guidance on Oct 28, 2026: Operating expenses +50% for FY2027; Operating expenses $70.0M–$75.0M for FY2027.
What does Lenz Therapeutics expect?
We expect to continue to incur significant expenses related to product sales, marketing, manufacturing, and distribution of VIZZ as we are in the early stages of commercialization, and additional costs associated with being a public company, including audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements. We expect to continue to incur expenses necessary to support our commercial strategy, including our direct-to-consumer (“DTC”) marketing campaign. We expect our selling, general and administrative expenses to dec
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.